COVID-19 Gives US Biopharma Plenty Of Q1 Cover
Pfizer, Merck, Eli Lilly and Gilead all benefited from the sale of vaccines and treatments for COVID-19, but the long-term growth prospects remain uncertain, and more so for some than others.
You may also be interested in...
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.